《異動股》永泰生物(06978.HK)逆市續漲逾13%屢創上市新高
永泰生物-B(06978.HK)連續第二天創上市新高,最高見21.75元,現造21.1元,續漲逾13%,成交進一步增至598萬股,涉資1.228億元。
永泰去年虧損按年擴大3倍至4.39億元人民幣,每股虧損0.99元人民幣。永泰是內地一家領先細胞免疫治療生物醫藥公司,13年來專注於T細胞免疫治療研發和商業化,公司核心在研產品EAL是內地首款獲准進入II期臨床試驗細胞免疫產品及當下唯一獲准進入實體瘤治療II期臨床試驗細胞免疫產品,該藥屬多靶點腫瘤細胞免疫治療產品,並對多種癌症顯示出治療效果。該股去年7月初以每股11元來港上市,淨籌約10.24億元。掛牌後,股價曾於去年11月初反覆回落至5.8元獲承接回升。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.